Organization
Hospital Clínic de Barcelona, Barcelona, Spain
3 abstracts
Abstract
Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.Org: Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain, Yale University School of Medicine, New Haven, CT, Sheba Medical Center, Ramat Gan, and Tel Aviv University, Tel Aviv, Israel, Rambam Medical Center, Haifa, Israel, HonorHealth Research Institute, Scottsdale, AZ,
Abstract
Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).Org: Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain, Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Hospital Clínic de Barcelona, Barcelona, Spain, Hospital Clínic Barcelona, Barcelona, Spain, Hospital Clinic de Barcelona, Barcelona, Spain,
Abstract
ASCORE, A 2-YEAR, OBSERVATIONAL, PROSPECTIVE MULTICENTRE STUDY OF SUBCUTANEOUS ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE: 1-YEAR INTERIM ANALYSISOrg: University Medicine Berlin, Berlin, Germany, Université Paris-Sud, Paris, France, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, University of Pavia and IRCCS S. Matteo Foundation, Pavia, Italy, Centre Hospitalier Universitaire de France, Lille, France,